Suscribirse

Expression of CD103 identifies human regulatory T-cell subsets - 20/08/11

Doi : 10.1016/j.jaci.2006.07.034 
Zoulfia Allakhverdi, PhD a, David Fitzpatrick, PhD c, Annie Boisvert, MSc a, Nobuyasu Baba, MSc b, Salim Bouguermouh, MD b, Marika Sarfati, MD, PhD b, Guy Delespesse, MD, PhD a,
a From the Allergy Laboratory 
b Immunoregulation Laboratory, CHUM Research Center, Notre-Dame Hospital, Montreal 
c Immunological Systems, Amgen Inc, Seattle 

Reprint requests: Guy Delespesse, MD, PhD, CHUM Research Center, Notre-Dame Hospital, Laboratory on Allergy, 1560 Sherbrooke East St, Pav Mailloux, M4211-K, Montreal, Quebec, Canada H2L-4M1.

Montreal, Quebec, Canada, and Seattle, Wash

Abstract

Background

Analysis of naturally occurring T regulatory CD4+ (nTreg) cells in human diseases is hampered by the lack of specific surface marker. Indeed, the CD25 antigen, which is typically used to identify nTreg cells, is also expressed on activated effector T cells.

Objective

We sought to examine whether CD4+ T cells bearing CD103 are suppressor cells, regardless of CD25 coexpression.

Methods

We first compared freshly isolated tonsillar CD103+CD25 cells with their CD103CD25high counterparts for their capacity to suppress T-cell response and their expression of FoxP3 mRNA. Next CD103 was induced on neonatal or adult CD4+ T cells stimulated with allogeneic dendritic cells, and the CD103+ and CD103 fractions were compared as above.

Results

Tonsillar CD4+CD103+CD25 T cells displayed comparable suppressive activity and contained similar amounts of FoxP3 mRNA as their CD103CD25high counterparts. In vitro–generated alloantigen-primed CD103+ cells coexpressed CD25, suppressed T-cell activation, and contained more FoxP3 mRNA than the CD103CD25+ cells isolated from the same cultures. Finally, neonatal alloreactive cells contained more CD103+ Treg cells than their adult counterparts and, unlike the latter, became hyporesponsive to the priming alloantigens.

Conclusions

The examination of CD103 and CD25 coexpression allows identification of 3 subsets of human CD4+ nTreg cells, and the detection of CD103 on CD4+ T cells identifies nTreg cells, regardless of CD25 coexpression.

Clinical implications

The greater induction of CD103+ suppressor cells by cord blood should be related to its successful clinical use as an alternative to adult bone marrow transplantation.

El texto completo de este artículo está disponible en PDF.

Key words : Human regulatory T cells, CD103, FoxP3, CD25, neonatal lymphocytes, dendritic cells, alloreactive T cells, TGF-β

Abbreviations used : DC, FITC, iDC, mDC, PE, TCR, Treg


Esquema


 Supported in part by a Canadian Institute of Health Research grant MOP 103957.
Disclosure of potential conflict of interest: D. Fitzpatrick is employed by and owns stock in Amgen. The rest of the authors have declared that they have no conflict of interest.


© 2006  American Academy of Allergy, Asthma and Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118 - N° 6

P. 1342-1349 - décembre 2006 Regresar al número
Artículo precedente Artículo precedente
  • Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children
  • Wasu Kamchaisatian, Watcharaphong Wanwatsuntikul, John W. Sleasman, Nutthapong Tangsinmankong
| Artículo siguiente Artículo siguiente
  • Persistent central memory phenotype of circulating Fel d 1 peptide/DRB10101 tetramer-binding CD4+ T cells
  • Elizabeth Alice Louise Bateman, Michael Roger Ardern-Jones, Graham Stuart Ogg

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.